55O_PR Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival by body weight and anti-drug antibody status

Annals of Oncology ◽

10.1093/annonc/mdv519.04 ◽

2015 ◽

Vol 26 ◽

pp. ix16 ◽

Cited By ~ 1

Author(s):

J.-S. Ahn ◽

C. Jackisch ◽

R. Hegg ◽

D. Stroyakovskiy ◽

B. Melichar ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Pathological Complete Response ◽

Complete Response ◽

Phase Iii ◽

Event Free Survival ◽

Her2 Positive ◽

Free Survival ◽

Subgroup Analyses

Download Full-text

1945 Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status

European Journal of Cancer ◽

10.1016/s0959-8049(16)30893-0 ◽

2015 ◽

Vol 51 ◽

pp. S313-S314

Author(s):

C. Jackisch ◽

R. Hegg ◽

D. Stroyakovskiy ◽

J.S. Ahn ◽

B. Melichar ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Pathological Complete Response ◽

Complete Response ◽

Phase Iii ◽

Event Free Survival ◽

Her2 Positive ◽

Free Survival ◽

Subgroup Analyses

Download Full-text

Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)

10.1158/0008-5472.sabcs13-s1-01 ◽

2013 ◽

Cited By ~ 6

Author(s):

M Piccart-Gebhart ◽

AP Holmes ◽

E de Azambuja ◽

S Di Cosimo ◽

R Swaby ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Survival ◽

Pathological Complete Response ◽

Complete Response ◽

Breast Cancer Survival ◽

Event Free Survival ◽

Her2 Positive ◽

Free Survival ◽

Positive Breast Cancer

Download Full-text

Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

The Oncologist ◽

10.1634/theoncologist.2018-0065 ◽

2018 ◽

Vol 23 (10) ◽

pp. 1137-1143 ◽

Cited By ~ 5

Author(s):

Kyung Hae Jung ◽

Beyhan Ataseven ◽

Mark Verrill ◽

Xavier Pivot ◽

Michelino De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Phase Iii ◽

Medical Conditions ◽

Her2 Positive ◽

Subgroup Analyses ◽

Breast Cancer Subgroup ◽

Phase Iii Study

Download Full-text

Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.585 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 585-585 ◽

Cited By ~ 2

Author(s):

Christian Jackisch ◽

Roberto Hegg ◽

Daniil Stroyakovskiy ◽

Jin Seok Ahn ◽

Bohuslav Melichar ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Pathologic Complete Response ◽

Complete Response ◽

Event Free Survival ◽

Her2 Positive ◽

Free Survival

Download Full-text

Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy

Tumor Biology ◽

10.1007/s13277-015-4325-y ◽

2015 ◽

Vol 37 (4) ◽

pp. 4873-4881 ◽

Cited By ~ 3

Author(s):

Shiwei Liu ◽

Xuening Duan ◽

Ling Xu ◽

Jingming Ye ◽

Yuanjia Cheng ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Pathological Complete Response ◽

Complete Response ◽

Event Free Survival ◽

Her2 Positive ◽

Free Survival ◽

Her2 Positive Breast Cancer ◽

Gli1 Expression ◽

Positive Breast Cancer

Download Full-text

63P Phase III SafeHer study subgroup analyses: Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients

Annals of Oncology ◽

10.1093/annonc/mdv519.12 ◽

2015 ◽

Vol 26 ◽

pp. ix16

Author(s):

M. Shing ◽

K.H. Jung ◽

B. Ataseven ◽

M. Verrill ◽

M. De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Phase Iii ◽

Lower Body ◽

Her2 Positive ◽

Asian Patients ◽

Lower Body Weight ◽

Subgroup Analyses

Download Full-text

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up

European Journal of Cancer ◽

10.1016/j.ejca.2016.03.087 ◽

2016 ◽

Vol 62 ◽

pp. 62-75 ◽

Cited By ~ 38

Author(s):

Christian Jackisch ◽

Roberto Hegg ◽

Daniil Stroyakovskiy ◽

Jin-Seok Ahn ◽

Bohuslav Melichar ◽

...

Keyword(s):

Pathological Complete Response ◽

Complete Response ◽

Phase Iii ◽

Event Free Survival ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Free Survival ◽

Randomised Study ◽

Study Association

Download Full-text

1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses

European Journal of Cancer ◽

10.1016/s0959-8049(16)30904-2 ◽

2015 ◽

Vol 51 ◽

pp. S318

Author(s):

K.H. Jung ◽

B. Ataseven ◽

M. Verrill ◽

M. De Laurentiis ◽

H.A. Azim ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Phase Iii ◽

Lower Body ◽

Her2 Positive ◽

Asian Patients ◽

Lower Body Weight ◽

Subgroup Analyses ◽

Phase Iii Study

Download Full-text

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

JAMA Oncology ◽

10.1001/jamaoncol.2015.0830 ◽

2015 ◽

Vol 1 (4) ◽

pp. 448 ◽

Cited By ~ 258

Author(s):

Roberto Salgado ◽

Carsten Denkert ◽

Christine Campbell ◽

Peter Savas ◽

Paolo Nuciforo ◽

...

Keyword(s):

Breast Cancer ◽

Pathological Complete Response ◽

Early Stage ◽

Tumor Infiltrating Lymphocytes ◽

Complete Response ◽

Early Stage Breast Cancer ◽

Event Free Survival ◽

Her2 Positive ◽

Free Survival ◽

Infiltrating Lymphocytes

Download Full-text

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

Annals of Oncology ◽

10.1093/annonc/mdt505 ◽

2014 ◽

Vol 25 (1) ◽

pp. 75-80 ◽

Cited By ~ 7

Author(s):

U. Nitz ◽

O. Gluz ◽

I. Zuna ◽

C. Oberhoff ◽

T. Reimer ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Darbepoetin Alfa ◽

Phase Iii ◽

Event Free Survival ◽

Free Survival ◽

Prospective Phase

Download Full-text